Cangene will exercise its right if it obtains a government contract for development.
Maxygen sold an option for the exclusive license of its MAXY-G34 protein therapeutic for acute radiation syndrome (ARS) to Cangene for $500,000. If Cangene is able to obtain a government development contract for this indication, it will pay Maxygen an initial licensing fee and a percentage of its net government contract revenues. Additional licenses may be purchased for subsequent government contracts related to treatment or prevention of ARS-associated neutropenia .
Cangene may also purchase both licenses with a one-time $30 million fee. Rights would expire two years after acquiring the initial license. Separately, Cangene submitted a bid to BARDA specifying the development of MAXY-G34 in ARS. Maxygen retains all rights to Maxy-G34 for commercial development in non-ARS therapeutic areas.
“We believe MAXY-G34 is particularly attractive for the ARS application as a potent, safe and long acting drug that can rapidly increase neutrophil levels,” comments Russell Howard, CEO of Maxygen. “In the recently completed Phase IIa study in breast cancer patients with chemotherapy-induced neutropenia, MAXY-G34 was shown to be safe, effective, and have a prolonged plasma half-life compared to Neulast.”
Maxygen to Delay Development of Lead Program and Cut 30% of Jobs (Oct. 23, 2008)
Astellas Pays Maxygen $10M Upfront for License to Preclinical Candidates for Autoimmune Disease (Sep. 19, 2008)
Maxygen Wins $3.4M Award for Vaccine Development (Aug. 27, 2008)
Bayer Pays $90M for Maxygen’s Preclinical Hemophilia Program (July 2, 2008)
Sanofi Pasteur Gains Rights to Maxygen’s Dengue Vaccine Program in Deal Worth $24.5M (Dec. 4, 2007)